The cytohormonal diagnosis under various oral contraceptives

Pyknotic index by Pundel's method and grade according to Schmitt were determined throughout the cycles in women taking combined, sequential, and progestagen minipill oral contraceptives. The vaginal smears were stained by the Papanicolaou technique. 695 smears from 132 women taking 1 mg lynestrenol and .1 mg mestranol showed the highest pyknotic index and the highest proportion of Grade 4 superficial cells on Day 6, although the maturity of the vaginal epithelium was not as marked as in controls. The pyknotic index fell gradually, but rose to a 2nd peak on Day 26. 45 women taking a sequential containing 7 tablets of .08 mg mestranol and 15 tablets of .075 mg mestranol and 2.5 mg lynestrenol provided 280 vaginal smears. Build-up of superficial cells was greatest in the 1st part of the cycle. The smears were Grade 4 on Days 7-9 and Grade 3 on Day 11. Pyknotic index was highest on Day 9 and fell gradually for the rest of the cycle. 415 smears were taken from 112 women using .5 mg chlormadinone acetate. Cytoplasmic development wa s highest on Day 14, and the curve resembled normal untreated cycles closely.     

Correlation of vaginal hormonal cytograms with cervical mucus symptoms as observed by women using the ovulation method of natural family planning

The first study was done in which vaginal hormonal cytograms were correlated with cervical mucus symptoms as charted by women using the ovulation method of natural family planning. Daily vaginal smears obtained by 67 women during 78 menstrual cycles provided the basis of the study. The women had used the ovulation method for at least three cycles and were not breast-feeding. All vaginal smears examined cytologically had a microbiologic diagnosis of lactobacilli. All the vaginal hormonal cytograms revealed ovulatory-type patterns. Karyopyknotic index (KPI) peak correlated with peak mucus day +/-2 days in 74, or 94.9%, of the cases, with a mean of peak mucus at +0.14 days. The average number of mucus days prior to the KPI peak was 6.1. Seven women also provided daily blood specimens for bioassay of luteinizing hormone (LH). KPI peaked with a mean of 0.7 days after the LH peak.     

Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human

Short courses of cyproterone acetate, a compound with progestational and antiandrogenic activities, were administered to normally menstruating women during different phases of the menstrual cycle to suppress growth and maturation of the follicles and corpus luteum function. Postovulatory administration of 20 mg of the drug daily for 8 days to two women delayed menstruation by 4 to 6 days, followed by prolonged bleeding and short post-treatment cycles. Plasma levels of progesterone were suppressed temporarily during therapy, but increased immediately after cessation of treatment. Administration of 10 mg of the drug for 8 days during the early follicular phase to two women resulted in irregular bleeding, short cycles, and decreased plasma levels of progesterone throughout the cycle. Reduction of the dose to 2.5 mg during the early follicular phase in two other women also resulted in irregular cycles. When the 2.5-mg dose was administered to three women from the 8th to the 15th days of the cycle, vaginal bleeding and cycle length were normal. Plasma levels of luteinizing hormone and progesterone were suppressed during therapy. In one subject, cervical mucus was found to be hostile to sperm penetration in all three treatment cycles. The results indicate that, with cyclic administration of low doses of cyproterone acetate to women during the late follicular phase, it may be possible to interrupt pituitary-ovarian function, as well as sperm transport through the cervical mucus.     

Detection of cervical immunoglobulin A in normal pregnancy

The aim of our study was to evaluate a feasible method to quantify the immunoglobulin A concentration in the cervical mucus of women with a normal singleton pregnancy. In 60 immunologic healthy pregnant women cervical mucus samples were taken at a random time in pregnancy using an absorbing cylindrical cotton-swab stick. In this cervical mucus immunoglobulin A concentration was measured by radial immunodiffusion. A vaginal bacterial swab was taken from each woman. Concentration of immunoglobulins in maternal serum was estimated. There was no statistically significant difference of cervical immunoglobulin A concentration between the investigated groups (p = 0.952): 18-24 gestational weeks (gw): 52.8 (6.6-258.4) mg/l; 25-29 gw: 89.3 (4.8-193.8) mg/l; 30-34 gw: 55 (1.4-326) mg/l; 35-40 gw: 59.2 (4-400.9) mg/l. Women with a normal vaginal flora showed a significantly higher cervical immunoglobulin A concentration than those with a pathological colonization: 92.2 (6.6-400.9) mg/l vs. 42.5 (1.4-326) mg/l (p < 0.05). The serum levels of immunoglobulins A, A1, A2, M and G do not correlate to cervical immunoglobulin A levels nor to gestational age. In normal pregnancy, cervical immunoglobulin A concentration does not change with advancing gestational age, but a pathological vaginal colonization seems to be associated with decreased immunoglobulin A levels.     

Billings自然避孕法应用中阴道细胞形态及LH水平观察

本文报道应用Billings自然避孕法时观察宫颈粘液和阴道细胞学的关系。67名妇女70周期提供了1587张阴道涂片,每例阴道涂片均显示乳酸杆菌及排卵型图象。KP1峰日在粘液峰日前后两天范围内的共有62周期,占88.6%,KP1峰日在粘液峰日后为0.01天。KP1峰日前共有粘液日为4.69天。10名妇女提供血和尿标本作血清LH 放射免疫及尿LH酶标测定。KPⅠ峰日在LH 峰日后为0.5天,粘液峰日在LH 峰日后为0.4天。     

Clomiphene citrate and its effects upon ovulation and estrogen

This paper reports a clinical evaluation of the mechanism of action of clomiphene citrate and describes selection of the most responsive patients. Patients were 121 women, aged 21-37 years, who desired pregnancy. Their infertility was diagnosed as being due to anovulation. Primary amenorrhea or special endocrine disorders were not present. All the women who had no vaginal bleeding for more than 2 months were diagnosed amenorrhea and treated with 65 mg of progesterone capronate intramuscularly. They were then divided into two subgroups on the basis of the presence or absence of vaginal bleeding within 2 weeks. Clinical studies included: basal body temperature charts; daily vaginal smears evaluated by the ink acidophilic stain index (ISI); cervical mucus evaluated by amount, spresence of spinnbarkeit, and ferning; 24-hour urines examined for estrogen and total gonadotropic activity; and a pregnanediol determination. Each group received daily 50 mg doses of clomiphene citrate for 5 days. Estrogen inhibiting effect of the drug was suggested by vaginal cytology and the disappearance of ferning and decrease in quantity of cervical mucus. However, the excretion of the total urinary estrogen was increased in ovulatory cases (81 of the 121 patients). In 17 patients having no bleeding within 2 weeks after progesterone injection no ovulation could be induced. In patients with withdrawal flow 54 of 70 achieved ovulation. Of 37 patients with previous anovulatory bleeding 27 achieved ovulation. There were 11 of the 121 who became pregnant. In those with early ovulation the antiestrogen effect is believed to be in the hypothalamus and pituitary bringing about the estrogen surge and stimulating LH secretion. In those with later ovulation the antiestrogenic effect increased FSH secretion followed by ovulation. The type of patient most likely to respond to clomiphene citrate is one with nearly normal pituitary-gonadal axis. Inducing withdrawal bleeding with progesterone in those amenarrheic patients who are to be treated with clomiphene citrate is believed to be a good method of anticipating the result of the treatment.     

Proteins of human vaginal fluid

Proteins of vaginal fluid from normal and hysterectomized women were identified and compared with those of cervical mucus. Albumin, alpha1-antitrypsin, alpha2-haptoglobin, alpha2-macroglobulin, beta-lipoprotein, orosomucoid, ceruloplasmin, gamma chains, gamma G. K. (Bence Jones), and immunoglobulins G, A, and M were present in both vaginal fluid and cervical mucus. Fibrin and C-reactive protein were not found in the vaginal fluid but were identified in cervical mucus. alpha2-Haptoglobin, alpha2-macroglobulin, beta-lipoprotein, orosomucoid, and immunoglobulin M were absent in the vaginal fluid of hysterectomized women, indicating that their presence in the vaginal secretion of normal women may be due to contamination from cervical mucus.     

Low dosage megestrol acetate application as contraceptive

A review of the development of low dose progesterone is presented. Continuous low-dose megestrol acetate therapy data from 43 patients is presented. When short cycle lengths, breakthrough bleeding, and amenorrhea occurred, a lower dose of megestrol acetate was substitute. 78% of the cycles varied between 21 and 38 days a breakthrough bleeding occurred in 19.6% cycles, and average flow was 5.2 days. There were no breakthrough pregnancies in this group. A majority of the cycles with megestrol acetate were ovulatory, but the cervical mucus was hostile and vaginal smears showed a definite progestational effect.     

Proliferation in "atypical" atrophic pap smears

OBJECTIVE: Atrophic cervical epithelium of postmenopausal women may mimic high-grade cervical intraepithelial neoplasia (CIN2-3) in Papanicolaou-stained cervical smears (Pap smears). Women with such an "atypical" Pap smear need a repeated Pap smear after a course of estrogens before a definite diagnosis can be made. The aim of this study was to determine whether measurement of proliferative activity in Pap smears of postmenopausal patients that were difficult to interpret is a reliable test for differentiating between cervical atrophy and high-grade CIN. METHODS: Pap smears obtained before and after estrogen treatment of 30 postmenopausal women with an atypical Pap smear were restained with the monoclonal antibody MIB1 to visualize proliferating cells. The proliferative activity index (PAI) was subsequently measured in order to explore the feasibility of a recently proposed PAI-based diagnostic decision tree to reduce the number of estrogen courses and follow-up Pap smears in postmenopausal women. RESULTS: The PAI-based test to discriminate between cervical atrophy and high-grade CIN resulted in 100 and 96% correct diagnoses in women with high-grade CIN and cervical atrophy, respectively. Only 2 of the 30 women would have needed a repeated Pap smear after estrogen treatment for definite diagnosis if the PAI-based diagnostic decision had been used. CONCLUSIONS: Measurement of PAI in MIB1 restained Pap smears is a simple, reliable, safe, and probably also cost-effective method to obtain a substantial reduction of diagnostic estrogen courses and subsequent Pap smears in postmenopausal women with an atypical Pap smear.     

Luteoma of pregnancy. Report of a case

264 women (about 50% private patients), all less than 40 years old and none with history contraindicating oral contraception, were started on a regimen with Ovral (.5 mg norgestrel and .05 mg ethinyl estradiol). Medication started on Day 5 of a menstrual cycle. Then therapy followed a 3 weeks on, 7 days off schedule. Patients continued for 1-22 cycles (mean 7 cycles) for a total of 1918 cycles. Despite the omission of 42 doses by 32 patients, no pregnancies occurred. The percentages of cycles with average flow, spotting, breakthrough bleeding, and dysmenorrhea were 74.4, 2.5, .4, and .6, respectively. The incidence of amenorrhea, .2%, was spectacularly low in comparison with findings in other studies. Papanicolaou smears (483) were all normal (Class I or II). Morphologic changes seen at endometrial biopsy (61) were similar to those produced by other available progestogen-estrogen compounds. No significant variation from control findings (1878) were found in 1463 laboratory studies. The studies included leukocyte and differential counts (724), and determinations of hemoglobin and hematocrit (388), fasting blood sugar and blood urea nitrogen (114), bilirubin and liver function (61), and renal function (176). Minor symptoms (nausea, vomiting, headache, etc.) were few and disappeared after the first few cycles. The preparation suppresses ovulation (probably through action of the estrogen), probably alters the cervical mucus to inhibit sperm penetration, possibly interferes with nidation, and may interfere with follicular development.     

Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones

Mucosal immunity in the female reproductive tract is influenced by immunoglobulins (Igs), cytokines, and reproductive hormones. Previous studies of reproductive-aged women demonstrated that IgA and IgG increases in cervical mucus corresponded to elevated levels of IL-1beta which occurred 1 day before the peak of endogenous estradiol production prior to ovulation. We sought to determine the effect of exogenous hormones on reproductive tract immunity in women on oral contraceptive pills (OCPs) and to compare the results with respect to naturally cycling women. Twelve women of reproductive age who had negative cervical cultures, a normal pap smear, and agreed to abstain from sexual intercourse during the study initiated OCPs. Cervical mucus and vaginal washes were collected at six intervals (2-3 days apart) throughout the treatment cycle. Fifteen naturally cycling women had similar samples collected prior to, during, and subsequent to ovulation. Cervical mucus samples were assayed for IgA, IgG, IL-1beta, IL-6, and IL-10 by enzyme-linked immunosorbent assay (ELISA). IgA, IgG and IL-1beta levels in women on OCPs paralleled increasing levels of norethindrone. Mean values of IgA increased from a low of 14.4+/-3.1 to 41.1+/-9.4 mg/dl and decreased significantly after the cessation of the pills (P < 0.001). In naturally cycling women, the largest quantities of Igs were detected prior to ovulation. By comparison, mean values of IgA in the cervical mucus of women on OCPs (24.4 mg/dl) exceeded peak levels of IgA in the cervical mucus of naturally cycling women (14.6 mg/dl). IgA was the predominant Ig detected in cervical mucus of women on OCPs. Both immunoglobulins in each group exhibited changes relative to their hormonal status. The increased levels of IgA in the cervical mucus of women on OCPs may explain the clinical observation of a lower incidence of sexually transmitted diseases.     

The significance of psammoma bodies in screening cervical cytologic smears

OBJECTIVE: Although the presence of psammoma bodies in cervical cytologic smears has been associated previously with gynecologic malignancies, the clinical significance of this finding in asymptomatic women who undergo routine cervical cytologic screening has not been well defined. STUDY DESIGN: For this retrospective clinicopathologic study, a search of the Virginia Mason Medical Center computerized cytology registry from 1993 through March 2002 identified 25 evaluable cervical cytologic smears that contained psammomatous calcifications. Slides were reviewed, and clinical information was obtained from medical records. RESULTS: The median patient age was 36 years (range, 22-72 years). Nine women were postmenopausal. All cytologic smears were obtained for routine screening, and no abnormal cells that were diagnostic of malignancy were identified. Possible explanations for the psammoma bodies was determined for 11 women, including foci of calcifications in benign endometrial or endocervical tissue (4 women), polyps (3 women), marked atrophy (3 women), postpartum (2 women), and follicular cervicitis (1 woman). None of the 25 women had cancer. After excluding 1 woman who was to lost to follow-up, the remaining 24 women were followed up for a median of 3 years (range, 6 months-7 years) without the subsequent detection of cancer. CONCLUSION: Cancers that were reported in previous studies usually were diagnosed in women with malignant background cytology or abnormal symptoms, such as postmenopausal bleeding. In contrast, our study suggests that the presence of psammoma bodies in normal cytologic smears of asymptomatic women is an incidental finding.     

Cigarette smoking and the degree of maturation of the vaginal squamous epithelium in postmenopausal women

To determine the effects of cigarette smoking on vaginal squamous epithelium in postmenopausal women, we studied the vaginal smear patterns of 199 healthy postmenopausal non-smokers and 41 healthy postmenopausal smokers, with a mean age of 56 years. A statistically significant difference to the hazard of smokers was found in the percentage of smears manifesting absence of maturation of vaginal squamous cells. A high incidence of atrophic-type vaginal smears in the group of smokers was also found independent of postmenopausal age. In the group of non-smokers, there was a statistically significant difference between the cytologic patterns of smears of women who were in the early postmenopausal age (<10 years) and those many years after (> or =10 years). Finally our data suggest that smokers had an earlier menopause, on average 2.4 years sooner than non-smokers. Cigarette smoking has an effect on vaginal squamous epithelium, but pathophysiology still remains unclarified.     

Influence of norethynodrel and mestranol upon cervical dysplasia and carcinoma in situ

A 3-year progress investigation of the results of continuing serial cytologic, cytochemical, colposcopic, histologic, and clinical studies i nvolving 782 women is reported. These patients were selected from 60,00 0 women by a cytodiagnostic screening group before medication was given. The drug used was the steroid contraceptive Enovid, a combination of 9.85 mg norethynodrel with .15 mg mestranol. The usual daily dose of Enovid was 2, 5, or 10 mg orally. Tablets were taken in 20 doses from D ay 5 to Day 24 of the menstrual cycles. In some, continuous therapy was given at the same dosage for 60-240 days. Response was not related to dosage. Medication was begun after a cell-diagnosis was made. Frequent periodic examinations were made of cells scraped from the squamo-columnal junction of the cervix. This method was considered much more accurate than smears from the vaginal area. Some were followed for 3-4 years. No case was found in which a lesion progressed to a stage of infiltration. In the 654 women found to have normal cytology, Enovid therapy appeared to have exerted no unfavorable influence. Of the 66 women who had preexisting inflammatory lesions with precancerous tendencies, slight progression was noted in 2 (6%) and remission in 20 (30%). In 42 (64%) no change was found after Enovid medication. Of 60 patients having marked dysplasia of cells or with beginning carcinoma in situ, 3 (5%) showed remission, 15 (25%) showed fluctuation of findings, and 42 (70%) showed unaltered expected progression. Cytochemical investigations included continuing fluorescent microscopic studies to evaluate changing levels of DNA and RNA, glycogen studies, and micropolysaccharide evaluations. It is concluded that Enovid showed no carcinogenic influence even in preexisting premalignant dysplasia or carcinoma in situ of the cervix. However, periodic examinations with cervical cytologic studies are recommended for those under Enovid medication.     

The significance of atypical glandular cells on routine cervical cytologic testing in a community-based population

OBJECTIVES: We sought to determine the follow-up rate of women with glandular atypia on routine Papanicolaou smears in a community-based population and to describe the associated pathologic findings. STUDY DESIGN: Over a 12-month period, all patients with Papanicolaou smears with atypical glandular cells of undetermined significance were reviewed for demographic and clinical characteristics and followed up for a period of 12 to 24 months. RESULTS: Of the 48,890 Papanicolaou smears examined, 141 (0.29%) were diagnosed with atypical glandular cells of undetermined significance. Of these, 22 (17.6%) had no record of any subsequent investigation, and only 64 (51.2%) were monitored with both colposcopy and biopsy. Of the 64 biopsy specimens, 39 (60.9%) were positive for disease. Twenty-six (66.7%) were of squamous origin, with the most advanced lesion being cervical intraepithelial neoplasia 3. An additional patient had a combined cervical intraepithelial neoplasia and adenocarcinoma in situ lesion. Four (10.3%) additional patients had glandular cervical lesions, 2 benign polyps and 2 adenocarcinoma in situ lesions. Seven (17.9%) patients had endometrial lesions (benign polyps, 2 patients; complex atypical endometrial hyperplasia, 1 patient; and endometrial carcinoma, 4 patients). One patient had ovarian cystadenocarcinoma. Postmenopausal women were 5 times more likely to have a glandular lesion. Women with abnormal vaginal bleeding were also more likely to have a glandular lesion. These same patient groups were also more likely to have endometrial disease. CONCLUSION: The incidence of atypical glandular cells of undetermined significance on Papanicolaou smears in this community-based population was 0.29%, which is consistent with estimates from institution-based populations. Nearly 50% of women studied were not followed up with tissue biopsy. Of those with a tissue biopsy, 61% had positive findings, including 5 with cancer. Although postmenopausal status and abnormal vaginal bleeding were associated with endometrial or glandular disease, studies of larger patient populations should be conducted to examine potential risk factors for these conditions.     

阴道给予丙酸睾丸素配伍米索前列醇在绝经后妇女取节育环中的应用

目的:探讨术前阴道预处理降低绝经后妇女取节育器(IUD)风险及痛苦的方法。方法:将240例绝经后取器的妇女随机分为3组,每组80例,A组:术前2周起每日使用20 g/L丙酸睾丸素鱼肝油软膏1 g/d,阴道涂抹,于取IUD前2～3 h阴道置入米索前列醇200μg;B组:术前连续7 d口服戊酸雌二醇(E2V)3 mg/d,直至手术日;C组:给予不含丙酸睾丸素鱼肝油软膏1 g/d阴道涂抹。观察手术时宫颈松弛程度、取器顺利程度、术中出血量、手术时间,采用目测模拟疼痛程度分级法评价各组疼痛程度;免疫发光分析法测定用药前、后血清雌二醇(E2)和睾酮(T)水平,B超测定子宫内膜厚度。结果:A组宫颈松弛程度、取器顺利程度、术中出血量、手术时间和疼痛程度显著优于C组(P<0.01),且出血少于B组(P<0.05)。外周性激素水平与子宫内膜无明显变化(P>0.05)。结论:术前阴道给予20 g/L丙酸睾丸素配伍米索前列醇用于绝经后妇女取IUD,降低了手术难度,减轻了患者的痛苦,安全有效,值得进一步研究与推广应用。     

Cervical immunoglobulin A and altered vaginal flora in pregnant women with threatened preterm delivery

The aim of our study was to investigate the cervical immunoglobulin A concentration in women with threatened preterm delivery. Immunoglobulin A concentration in the cervical mucus of 80 women with symptoms of preterm delivery was measured using radial immunodiffusion. The results were compared with those of 60 healthy pregnant women. Concentrations of immunoglobulins in maternal serum were also measured. There was no significant difference of cervical immunoglobulin A (IgA) concentration between women with threatened preterm delivery and controls: 53.98 (0.0-189.7) mg/l vs. 61.7 (1.4-400.9; p<0.4) mg/l (median, range). The median of cervical IgA levels in the group of threatened preterm delivery did not differ significantly between patients delivered preterm (n=34) or at term (n=46): 38.3 (0.0-187.9) vs. 65.7 (1.4-189.7; p<0.2) mg/l. Women with a normal vaginal flora showed a significantly higher cervical IgA concentration than those with a pathological colonization: 72.7 (0.0-187.9) vs. 42.5 (0.0-189.7) mg/l. Patients with a pathological vaginal smear and preterm delivery had the lowest IgA levels (35.0; 0.0-187.9 mg/l). Measurement of cervical IgA concentration does not differentiate between women who deliver before or at term.     

Ureaplasma urealyticum (T-mycoplasma) in vaginal fluid and cervical mucus from fertile and infertile women

Ureaplasma urealyticum (T-mycoplasma) was isolated more frequently and in heavier growth from cervical mucus (49%) than from vaginal fluid (34%). It was isolated in 24% of vaginal fluid samples and in 35% of cervical mucus samples from fertile women, and in 29% of vaginal fluid samples and in 47% of cervical mucus samples from infertile women. The incidence of infection was high following abortion or total hysterectomy and during pregnancy or oral contraceptive use. T-mycoplasma was also isolated from the vaginal fluid and cervical mucus of a woman with tubo-ovarian abscess, but was not present in women with Trichomonas vaginalis infection. U. urealyticum did not alter the physiophysiologic characteristics of vaginal fluid and cervical mucus or the sperm penetration and sperm viability in cervical mucus. Treatment with tetracycline eradicated the organism in 88% of the infected women. Pregnancies were recorded during a 6-month follow-up in 1 of 19 infertile women who were treated with tetracycline.     

Cytologic examination to detect clear cell adenocarcinoma of the vagina or cervix

OBJECTIVE: The aim of this study was to determine the sensitivity of cytopathologic examination for the detection of vaginal or cervical clear cell adenocarcinoma (CCA). METHODS: Systematic collection in the Dutch automated nationwide pathology archive of all cytology and histology data of women with CCA, born in The Netherlands after 1947 was performed. All cytologic examinations within 2 years prior to histological diagnosis of CCA were included. RESULTS: Ninety patients with CCA have been registered. Forty-nine of these patients had cytologic examinations prior to histology. Eighty-five percent of cervical CCAs were preceded by a positive cervical smear. One hundred percent of vaginal CCAs were preceded by a positive vaginal smear. Cervical smears are relatively insensitive to detect vaginal CCA. Vaginal smears were often omitted. Only 2 apparently false-negative smears were found. The mean numbers of smears in diethylstilbestrol (DES)-exposed and nonexposed women were minimally different: 1.0 and 0.8, respectively. This suggests an only modest impact of the awareness of DES as a risk factor. FIGO tumor stage I was preceded more frequently by cytology than the higher tumor stages. CONCLUSION: The majority of CCA cases can be detected at an early stage by yearly clinical and cytological examinations, which must comprise cervical as well as vaginal sampling. Since CCA may also occur in postmenopausal women, for the purpose of secondary prevention of CCA regular cytologic examinations of DES-exposed women must be continued after menopause.     

Comparative studies of the estrogenic potency of mestranol and stilbestrol

90 women with absent or deficient estrogenic activity were administered by means of normal substitution therapy in a routine 10-day cycle mestranol in doses of .02, .05, and .1 mg, and stilbestrol in doses of 1.0 and 2.0 mg. Estrogen potency was measured through changes in the vaginal epithelium. Cytohormonal vaginal smears were taken before and after therapy; evaluation was made on the basis of maturation index, superficial cells index, and maturation value. With the value of '100' given to the estrogenic activity of 1 mg of stilbestrol, with an identical effect observed with .5 mg of mestranol, a value of '180.3' was given for .1 mg of mestranol, and '163' for 2.0 mg of stilbestrol. The dose of .02 mg of stilbestrol showed the lowest value of '34.7.'